With only $4.3M cash and a $3.0M quarterly burn rate, CollPlant faces imminent liquidity risk absent a strategic transaction or additional financing. The strategic alternatives review (including potential sale) creates a binary event: either a deal provides a floor, or the company runs out of cash within ~5 months. Monitor for any definitive agreement announcement or further dilutive financing.
Price Chart
Executive Summary
CollPlant reported Q1 2026 revenue of $73K, down 96% YoY from $2.1M due to a non-recurring $2.0M milestone payment in Q1 2025. GAAP net loss widened to $3.1M ($0.23/share) from $1.5M ($0.13/share). Cash burn accelerated to $3.0M from $1.2M, leaving $4.3M in cash. Management initiated a formal strategic alternatives review, including potential M&A or business combinations, while also cutting headcount ~50% to preserve cash.
Key Facts
- Q1 2026 revenue was $73,000 vs $2.1M in Q1 2025, a 96% decline driven by a non-recurring $2.0M milestone payment from a former collaborator
- GAAP net loss was $3.1M ($0.23/share) vs $1.5M ($0.13/share) in Q1 2025
- Cash and cash equivalents fell to $4.3M at March 31, 2026 from $5.6M at December 31, 2025
- Net cash used in operations was $3.0M in Q1 2026 vs $1.2M in Q1 2025
- Headcount reduced by approximately 50% as part of cost-cutting measures
- Company initiated a formal process to evaluate strategic alternatives including potential acquisitions, strategic transactions, and business combinations
- February 2026 registered direct offering raised $1.7M in net proceeds
- Shares outstanding increased to 14,423,253 from 12,803,006 at year-end 2025, a 12.7% dilution
Financial Impact
Revenue collapsed 96% YoY to $73K; net loss doubled to $3.1M; cash burn rate of $3.0M/quarter implies ~1.4 quarters of runway at current cash balance of $4.3M
Risk Factors
- Cash runway of approximately 1.4 quarters at current burn rate without additional capital or strategic transaction
- Strategic alternatives review may not result in any transaction, leaving the company with no clear path to solvency
- 12.7% dilution from February 2026 offering further pressures existing shareholders
- No recurring revenue base; revenue dependent on milestone payments from partners that may not materialize
- Pre-revenue clinical-stage company with no approved products and uncertain regulatory timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-062423 |
| Document: ea0292530-6k_collplant.htm | 0001213900-26-062423 |
| Document: 0001213900-26-062423-index-headers.html | 0001213900-26-062423 |
| Document: 0001213900-26-062423-index.html | 0001213900-26-062423 |
| Document: 0001213900-26-062423.txt | 0001213900-26-062423 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 144 | $3.78 | awaiting T+1 | — | $3.90 (+3.17%) |
Oct 19, 2026 8d ago | 3 | $3.88 $3.76 | ▼ −3.22% | ▼ −3.75% | $3.90 (+0.52%) |
Oct 15, 2026 12d ago | 6-K | $3.68 $3.63 | ▲ +1.49% | ▲ +0.39% | $3.90 (−5.98%) |
Oct 9, 2026 18d ago | 6-K | $4.02 $3.91 | ▲ +2.74% | ▲ +2.72% | $3.90 (+2.99%) |
Oct 8, 2026 19d ago | SC 13G | $3.97 $3.51 | ▼ −11.59% | ▼ −12.19% | $3.90 (−1.76%) |
Oct 8, 2026 19d ago | SC 13D/A | $3.97 $3.51 | ▼ −11.59% | ▼ −12.19% | $3.90 (−1.76%) |
Oct 6, 2026 21d ago | 6-K | $3.39 $3.46 | ▲ +2.06% | ▲ +2.30% | $3.90 (+15.04%) |
Sep 30, 2026 27d ago | 6-K | $3.57 $3.46 | ▲ +3.08% | ▲ +3.82% | $3.90 (−9.24%) |
Sep 30, 2026 27d ago | Press Release | $3.57 $3.46 | ▲ +3.08% | ▲ +3.82% | $3.90 (−9.24%) |
Sep 24, 2026 4w ago | 6-K | $4.12 $4.25 | ▲ +3.16% | ▲ +2.61% | $3.90 (−5.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers